Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Designed under ISO 9001:2015 and ISO 13485:2016
Manufactured and QC tested under a GMP compliance factory
FDA DMF filed
Animal-Free materials
Beta-lactam materials free
Batch-to-batch consistency
Stringent quality control tests
This protein carries no "tag".
The protein has a calculated MW of 12.8 kDa. The protein migrates as 13 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 100 mM HAC, pH3.0 with protectants.
Contact us for customized product form or formulation.
This product is supplied and shipped with blue ice, please inquire the shipping cost.
Upon receipt, store it immediately at -20°C or lower for long term storage.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
GMP Human TGF-Beta 1 Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) inhibits the GMP Human IL-4 Protein (Cat. No. GMP-L04H26) dependent proliferation the TF-1 cells. The specific activity of GMP Human TGF-Beta 1 Protein is > 6.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code:89/514) (QC tested).
The activity of GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) was higher than other competing products.
GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) and GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) could maintain the stemness of hiPSCs with high expression of stem cell genes OCT4, SOX2, and SSEA4 with GMP Human Laminin 521 Protein (Cat. No. GMP-LA5H24).
The Cell based assay shows that GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) is stable at 37°C for 24 hours.
The Cell based assay shows that GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) is stable at 4°C for 180 days.
The Cell based assay shows that GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) is stable after freezing and thawing 3 times.
The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG TGF-Beta 1.
ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.
ACROBiosystems Quality Management System Contents:
Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory
Animal-Free materials
Materials purchased from the approved suppliers by QA
ISO 5 clean rooms and automatic filling equipment
Qualified personnel
Quality-related documents review and approve by QA
Fully batch production and control records
Equipment maintenance and calibration
Validation of analytical procedures
Stability studies conducted
Comprehensive regulatory support files
Request For Regulatory Support Files(RSF)
ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:
SDS-PAGE
Protein content
Endotoxin level
Residual Host Cell DNA content
Residual Host Cell Protein content
Biological activity analysis
Microbial testing
Mycoplasma testing
In vitro virus assay
Batch-to-batch consistency
Price(USD) : $565.00
Price(USD) : $6950.00
Price(USD) : $9690.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tonogenchoncel-L | TG-C | Approved | Tissuegene | Invossa-K, Invossa | South Korea | Osteoarthritis | null | 2017-07-01 | Intervertebral Disc Degeneration; Osteoarthritis, Knee; Osteoarthritis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vactosertib | TEW-7197; EW-7197; NOV-1301 | Phase 3 Clinical | Medpacto Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Myeloproliferative Disorders; Osteosarcoma; Colorectal Neoplasms; Urologic Neoplasms; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Brain metastases; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Thymus Neoplasms; Oropharyngeal Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Lymphoma; Penile Neoplasms; Thymoma; Urogenital Neoplasms; Metastatic breast cancer; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Vaginal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Anus Neoplasms; Biliary Tract Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Nose Neoplasms; Ganglioglioma; Papillomavirus Infections; Carcinoma, Trans | Details |
Nisevokitug | NIS-793 | Phase 3 Clinical | Xoma Corp | Kidney Neoplasms; Polycythemia Vera; Pancreatic Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma; Thrombocythemia, Essential; Carcinoma, Hepatocellular | Details |
SB-01 (Ensol BioSciences) | Peniel-2000; SB-01; Peniel 2K; YH14618; YH-14618; P2K | Phase 3 Clinical | Ensol Biosciences Inc | Intervertebral Disc Degeneration; Intervertebral disc disease; Low Back Pain | Details |
Livmoniplimab | MGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115 | Phase 3 Clinical | Argenx Se | Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Dalutrafusp alfa | GS-1423; AGEN-1423 | Phase 2 Clinical | Agenus Inc | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
ZSP-1603 | ZSP-1603 | Phase 2 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Idiopathic Pulmonary Fibrosis; Colonic Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Nicousamide | XLF-III-43 | Phase 2 Clinical | Institue Of Materia Medica Chinese Academy Of Medical Science | Hypertensive nephropathy; Diabetic Nephropathies | Details |
Meflonidone hydrochloride | Phase 2 Clinical | Guangzhou Nanxin Pharma Co Ltd, Central South University | Diabetes Mellitus, Type 2; Diabetic Nephropathies | Details | |
Fluorofenidone | AKF-PD | Phase 2 Clinical | Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University | Liver Cirrhosis | Details |
Cotsiranib | STP-705LU; STP-705LV; STP-705; STP-705L | Phase 2 Clinical | Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Liver Neoplasms; Carcinoma, Basal Cell; Cholangiocarcinoma; Carcinoma, Basosquamous; Obesity, Abdominal; Keloid; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular | Details |
Yinfenidone Hydrochloride | HEC-585; HEC-00000585 | Phase 2 Clinical | Hec Pharm Co Ltd | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
YL-13027 | YL-13027 | Phase 2 Clinical | YL-Pharma | Solid tumours; Pancreatic Neoplasms | Details |
Linavonkibart | SRK-181; SRT-BETA-1-AB3 | Phase 1 Clinical | Scholar Rock | Neoplasms | Details |
Charis-1000 | Charis-1000; C 1K; C1K | Phase 1 Clinical | Ensol Biosciences Inc | Breast Neoplasms | Details |
HLX-6018 | HLX-6018; HLX6018 | Phase 1 Clinical | Shanghai Henlius Biopharmaceuticals Co Ltd, Shanghai Henlius Biotech Inc | Idiopathic Pulmonary Fibrosis | Details |
RO7496353 | RO7496353; RO-7496353; SOF 10; RG6440; RG-6440 | Phase 1 Clinical | Genentech Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
JYB-1907 | JYB-1907 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Solid tumours | Details |
STP-707 | STP-707; STP707 | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing | Details |
PXS-64 | PXS-64 | Phase 1 Clinical | Syntara Ltd | Multiple Sclerosis | Details |
AVID-200 | AVID-200; BMS-986416; AVID-200 DP | Phase 1 Clinical | Formation Biologics Corp | Solid tumours; Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Thrombocythemia, Essential | Details |
This web search service is supported by Google Inc.